Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-17509
- Development stage
- Phase 1
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BPI-17509 is an orally bioavailable, small-molecule pan-FGFR inhibitor developed by Betta Pharmaceuticals. It is designed to selectively target and inhibit fibroblast growth factor receptors, specifically FGFR1, FGFR2, and FGFR3. These receptors are frequently dysregulated in various malignancies through mechanisms such as gene fusions, mutations, or amplifications, leading to constitutive signaling that promotes cell proliferation, survival, and angiogenesis. BPI-17509 is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors, with a particular focus on patients harboring FGFR aberrations, including FGFR2 fusion-positive cholangiocarcinoma and FGFR3-altered bladder cancer.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on BPI-17509.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-17509.